HCA

HCA Healthcare, Inc. (HCA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. HCA Healthcare, Inc. operates 191 hospitals, 123 freestanding surgery centers, and 29 freestanding endoscopy centers across 20 U.S. states and England. The company is a large accelerated filer with 228.2 million shares of voting common stock outstanding as of October 27, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenues increased 9.6% year-over-year, driven by a 6.1% increase in revenue per equivalent admission and a 3.2% increase in equivalent admissions. Same-facility revenue grew 9.2%.
• Profitability: Net income attributable to HCA rose 29.4% in Q3 2025. This compares favorably to Q3 2024, which included approximately $50 million in expenses and lost revenue due to Hurricane Helene.
• Cost Management: Salaries and benefits as a percentage of revenue decreased to 43.6% in Q3 2025 from 45.0% in Q3 2024, attributed to labor management initiatives.
• Facility Transactions: In the first nine months of 2025, the company recognized a $4 million loss on sales of facilities, compared to a $209 million gain in the same period of 2024.
• Debt Restructuring: In February 2025, HCA repaid $2.6 billion in senior notes due at maturity and entered a new $8.0 billion senior unsecured revolving credit facility, replacing previous secured facilities.

Guidance, Outlook, and Risks

• Legislative Impact (OBBBA): The "One Big Beautiful Bill Act" (OBBBA), enacted July 4, 2025, reinstates 100% bonus depreciation but is expected to decrease access to health insurance and reduce federal spending, particularly in Medicaid. It may trigger a 4% reduction in Medicare reimbursements in early 2026 due to Pay-As-You-Go sequestration.
• Government Shutdown: A partial federal government shutdown began October 1, 2025. While Medicare/Medicaid reimbursements generally continue, payment delays are possible. Medicaid Disproportionate Share Hospital (DSH) payment reductions of $8.0 billion began October 1, 2025, though Congress has historically deferred these.
• Capital Allocation: The company repurchased $7.509 billion of common stock in the first nine months of 2025. As of September 30, 2025, $3.256 billion of repurchase authorization remains available. A quarterly dividend of $0.72 per share was declared on October 23, 2025.
• Liquidity: Working capital turned negative ($2.611 billion) due to increased short-term borrowings and accrued expenses, though management cites strong operating cash flow and credit facility availability to meet liquidity needs.

Investor Verification Checklist

• Medicaid Funding: Verify the status of state supplemental payment programs and the potential impact of OBBBA limitations on provider taxes and State Directed Payments (SDP).
• Uncompensated Care: Monitor the estimated cost of total uncompensated care, which was $1.188 billion in Q3 2025, and the trend in uninsured admissions (down 1.3% consolidated).
• Debt Maturity Profile: Review the $6.110 billion in debt due within one year and the company's strategy to refinance this using the new $8.0 billion credit facility or commercial paper program.
• Regulatory Audits: Note that the IRS concluded examinations for 2022 and 2023 but is currently examining 2019 returns; assess potential liability for unrecognized tax benefits ($515 million gross).
• Volume Trends: Confirm the sustainability of the 6.1% increase in revenue per equivalent admission amidst potential policy-driven volume declines.